1 Dividend King to Buy Before the New Year and Hold Forever

Colgate-Palmolive shares rose 12.3% in October, bringing their 2026 year-to-date gain to 23.4%, as investors rotated toward consumer staples during a 6.6% Nasdaq-100 decline. In Q3, EPS increased 3% and organic sales rose 3.6%; the company narrowed its full-year revenue growth outlook to 4%-5% from 2%-6% and said it now expects gross profit margin to rise rather than remain flat. North American sales were lethargic, but global markets helped offset weakness, and the article notes possible—but unconfirmed—sales of personal-care brands.

Analysis

The key issue is whether pricing power is converting into durable unit economics, not whether CL can retain a defensive label. If price increases are supporting gross margin without sustained volume loss, the company can protect earnings through inflation; if shoppers trade down, current resilience may be pulled forward demand rather than a stable growth rate. North American softness makes that distinction worth monitoring, while global growth adds exposure to currency and region-specific demand swings.

Near term, October’s defensive rotation can support the shares, but it also raises reversal risk: a tech rebound or higher real yields could unwind flows into staples, particularly after CL’s strong run. Over 1–3 months, the evidence to watch is organic volume versus price/mix and delivery against the revised margin outlook. Over 6–18 months, any personal-care divestiture could sharpen capital allocation, but proceeds are not value creation by themselves; confirm price, lost earnings, and whether overhead can be removed before assigning upside.

Contrarian view: the dividend record may anchor ownership, but it does not insulate the multiple from a rotation reversal or from slowing volume. The article’s case is constructive on operating momentum, yet the marginal buyer may be paying for both defensiveness and recent outperformance. That argues for staged exposure, not chasing the rally.

Key Decisions for Investors

• Do not add aggressively after the sharp run. For a strategic CL position, scale in on a broad staples pullback rather than treating dividend history as a valuation floor.
• Set an earnings watch: track organic volume separately from pricing and verify that gross-margin improvement is delivered. Persistent volume deterioration or a retreat from the margin outlook would falsify the pricing-power thesis and warrant reducing exposure.
• Treat a sale of Irish Spring, Speed Stick, or other brands as an event-driven watch item, not a buy catalyst until terms are disclosed. Reassess on proceeds, earnings removed, and evidence of lower debt or reinvestment returns; a sale without credible redeployment may be neutral or dilutive.
• For the next 1–3 months, monitor real yields and consumer-staples flows. A reversal toward growth stocks would challenge the momentum case; avoid adding solely on defensive-sector inflows.